93 related articles for article (PubMed ID: 16130523)
1. Mutations in both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology.
Hantson A; Fikkert V; Van Remoortel B; Pannecouque C; Cherepanov P; Matthews B; Holan G; De Clercq E; Vandamme AM; Debyser Z; Witvrouw M
Antivir Chem Chemother; 2005; 16(4):253-66. PubMed ID: 16130523
[TBL] [Abstract][Full Text] [Related]
2. env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors.
Fikkert V; Cherepanov P; Van Laethem K; Hantson A; Van Remoortel B; Pannecouque C; De Clercq E; Debyser Z; Vandamme AM; Witvrouw M
Antimicrob Agents Chemother; 2002 Dec; 46(12):3954-62. PubMed ID: 12435701
[TBL] [Abstract][Full Text] [Related]
3. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
[TBL] [Abstract][Full Text] [Related]
4. High HIV Type 1 prevalence and wide genetic diversity with dominance of recombinant strains but low level of antiretroviral drug-resistance mutations in untreated patients in northeast Gabon, Central Africa.
Mintsa-Ndong A; Caron M; Plantier JC; Makuwa M; Le Hello S; Courgnaud V; Roques P; Kazanji M
AIDS Res Hum Retroviruses; 2009 Apr; 25(4):411-8. PubMed ID: 19320567
[TBL] [Abstract][Full Text] [Related]
5. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A
J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930
[TBL] [Abstract][Full Text] [Related]
6. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
[TBL] [Abstract][Full Text] [Related]
7. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
[TBL] [Abstract][Full Text] [Related]
8. Genetic and structural analysis of HIV-1 Rev responsive element related to V38A and T18A enfuvirtide resistance mutations.
Dimonte S; Mercurio F; Svicher V; Perno CF; Ceccherini-Silberstein F
Intervirology; 2012; 55(5):385-90. PubMed ID: 22188777
[TBL] [Abstract][Full Text] [Related]
9. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.
Este JA; Schols D; De Vreese K; Van Laethem K; Vandamme AM; Desmyter J; De Clercq E
Mol Pharmacol; 1997 Jul; 52(1):98-104. PubMed ID: 9224818
[TBL] [Abstract][Full Text] [Related]
10. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
11. Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping.
Robinson LH; Gale CV; Kleim JP
J Virol Methods; 2002 Jul; 104(2):147-60. PubMed ID: 12088824
[TBL] [Abstract][Full Text] [Related]
12. In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations.
Goubard A; Clavel F; Mammano F; Labrosse B
Antivir Ther; 2009; 14(4):597-602. PubMed ID: 19578246
[TBL] [Abstract][Full Text] [Related]
13. Characterization of resistance to a potent D-peptide HIV entry inhibitor.
Smith AR; Weinstock MT; Siglin AE; Whitby FG; Francis JN; Hill CP; Eckert DM; Root MJ; Kay MS
Retrovirology; 2019 Oct; 16(1):28. PubMed ID: 31640718
[TBL] [Abstract][Full Text] [Related]
14. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene.
Van Laethem K; Schrooten Y; Lemey P; Van Wijngaerden E; De Wit S; Van Ranst M; Vandamme AM
J Virol Methods; 2005 Jan; 123(1):25-34. PubMed ID: 15582695
[TBL] [Abstract][Full Text] [Related]
15. Functional characteristics of the natural polymorphisms of HIV-1 gp41 in HIV-1 isolates from enfuvirtide-naïve Korean patients.
Shin Y; Yoon CH; Yang HJ; Lim H; Choi BS; Kim SS; Kang C
Arch Virol; 2016 Jun; 161(6):1547-57. PubMed ID: 26997611
[TBL] [Abstract][Full Text] [Related]
16. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients.
Yaotsè DA; Nicole V; Roch NF; Mireille PD; Eric D; Martine P
Infect Genet Evol; 2009 Jul; 9(4):646-52. PubMed ID: 19460333
[TBL] [Abstract][Full Text] [Related]
17. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.
de Vreese K; Kofler-Mongold V; Leutgeb C; Weber V; Vermeire K; Schacht S; Anné J; de Clercq E; Datema R; Werner G
J Virol; 1996 Feb; 70(2):689-96. PubMed ID: 8551604
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing.
Blair WS; Cao J; Jackson L; Jimenez J; Peng Q; Wu H; Isaacson J; Butler SL; Chu A; Graham J; Malfait AM; Tortorella M; Patick AK
Antimicrob Agents Chemother; 2007 Oct; 51(10):3554-61. PubMed ID: 17646410
[TBL] [Abstract][Full Text] [Related]
19. Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry.
Witvrouw M; Pannecouque C; Fikkert V; Hantson A; Van Remoortel B; Hezareh M; De Clercq E; Brown SJ
Antivir Chem Chemother; 2003 Nov; 14(6):321-8. PubMed ID: 14968938
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the HIV-1 gp41 env gene, natural resistance to enfuvirtide (T-20) and pol resistance among pregnant Brazilian women.
Reis MN; de Alcântara KC; Cardoso LP; Stefani MM
J Med Virol; 2014 Jan; 86(1):8-17. PubMed ID: 24037943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
